Here, we describe the generation, characterization, and humanization of a novel monoclonal antibody directed against the transmembrane receptor Plexin-B1 that exerts therapeutic effects in mouse models of osteoporosis and MS with a mechanism distinct from all approved drugs. This evidence concerns the gene PLXNB1 and osteoporosis.